Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for advanced or metastatic anaplastic thyroid carcinoma
ChiCTR-OPC-17012676Phase 4Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of latanoprost in anaplastic thyroid cancer (ATC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Disease control rate. Started Sep 2017; status: recruiting.
02
Drugs
latanoprost
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on ChiCTR-OPC-17012676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17012676.